Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies.
The last earnings update was 45 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Geron. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Geron's earnings available for a low price, and how does
this compare to other companies in the same industry?
Geron is not considered high growth as it is expected to be loss making for the next 1-3 years.
Geron's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Geron's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. John A. Scarlett, also known as Chip, M.D., has been the Chief Executive Officer of Geron Corporation since joining in September 2011 and its President since January 5, 2012. Dr. Scarlett is Chairman of the Board at Geron Corporation since December 27, 2018. Dr. Scarlett served as Chief Executive Officer and President of Onyx Therapeutics, Inc. since February 2009. He Co-Founded Ipsen Biopharmaceuticals, Inc. (Formerly Tercica Inc) in 2002 and served as its Chief Executive Officer from February 2002 to October 2008. Dr. Scarlett served as Chief Executive Officer and President of Proteolix, Inc. from February 2009 to November 2009. Dr. Scarlett has nearly 30 years of experience in drug development and commercialization. He served as President of Ipsen Biopharmaceuticals, Inc., from February 2002 to February 27, 2008. From March 1993 to May 2001, Dr. Scarlett served as President and Chief Executive Officer of Sensus Drug Development Corporation. Prior to Tercica, Dr. Scarlett founded Sensus Drug Development Corporation. He Co-founded Covance Biotechnology Services, Inc., in 1995. From 1991 to 1993, he headed the North American Clinical Development Center and served as Senior Vice President of Medical and Scientific Affairs at Novo Nordisk A/S. From 1985 to 1990, Dr. Scarlett served as Vice President of Clinical Affairs and headed the clinical development group of Greenwich Pharmaceuticals, Inc. From 1982 to 1985, he served as Associate Director and subsequently, as Director, of Medical Research and Services of McNeil Pharmaceuticals, a wholly-owned subsidiary of Johnson & Johnson, Inc. He has been an Independent Director of Chiasma, Inc. since February 24, 2015. He serves as Director of Onyx Therapeutics, Inc. He has been a Director of Geron Corporation since September 2011 and CytomX Therapeutics, Inc. since June 13, 2016. Dr. Scarlett served as Director of Ipsen Biopharmaceuticals, Inc. from February 2002 to October 2008. He served as a member of board of directors of Covance Biotechnology Services, Inc. since 2000 and Proteolix, Inc. from February 2009 to November 2009. He received his B.A. degree in chemistry from Earlham College and his M.D. from the University of Chicago, Pritzker School of Medicine. Dr. Scarlett trained in Internal Medicine at the Hospital at the University of Pennsylvania and his fellowship in Endocrinology and Metabolism at the University of Colorado Health Sciences Center.
Chip's compensation has increased whilst company is loss making.
Chip's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Geron management team is over 5 years, this suggests they are a seasoned and experienced team.
CEO, President & Chairman of the Board
Executive VP of Finance
Executive VP & COO
Melissa A. Behrs
Executive VP & Chief Business Officer
Head of Investor Relations & Corporate Communications
Executive VP & Chief Medical Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Geron board of directors is about average.
Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.